AstraZeneca strikes pay-for-performance deal with UPMC Health Plan

(By Alia Paavola for Becker’s Hospital Review)

AstraZeneca has agreed to a pay-for-performance deal with UPMC Health Plan, according to STAT.

Under the deal, UPMC Health plan will pay for AstraZeneca’s blood thinner Brilinta based on how well patients respond. If Brilinta, used in patients who have suffered a heart attack, fails to prevent another attack within 12 months, UMPC will pay less for the drug. If Brilinta prevents a heart attack in the 12-month period, the health plan will pay more for the drug.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.